Experts urge FDA on diabetes medication

Further diabetes reports indicate that the expert panel being consulted by the Food and Drug Administration in America is calling for potential diabetes drugs to be reviewed in terms of their heart risks before approval.
The advisory panel helping the FDA could cause a major change in legislation. The change could require drug manufacturers to change their diabetes trials, and potentially delay new drugs entering the market.
The concerns and change was prompted by major public outcry against diabetes drug Avandia, which reportedly increases risk of heart disease and death. The experts advising the FDA voted overwhelmingly for companies to do long-term cardiovascular studies.